Lovastatin
Product Images NDC 50436-6601

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lovastatin (NDC 50436-6601). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Services, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl504366601)

Lovastatin 20 mg tablet label from Unit Dose Services. The label includes the product name, strength, dosage form (90 tablets), NDC 50436-6601-3, and manufacturer information for Carlsbad Technology, Inc. Instructions for storage and warnings about keeping the medicine out of reach of children are also visible. The label includes a barcode and lot and expiration date placeholders.*

FDA Label Image

Structural Formula (Lov00 0004 01)

Chemical structure of lovastatin showing its molecular arrangement with multiple ring systems and functional groups.*

FDA Label Image

Table I (Lov00 0004 02)

A data table titled 'The Effect of Other Drugs on Lovastatin Exposure When Both Were Co-administered' presenting information on the number of subjects, dosing of coadministered drugs or grapefruit juice, dosing of Lovastatin, and AUC Ratios comparing Lovastatin exposure with and without coadministered drugs. It includes data for various drugs such as Gemfibrozil, Itraconazole, Grapefruit Juice at different doses, Cyclosporine, and Diltiazem, with corresponding dosing regimens and effect ratios.*

FDA Label Image

Figure 1 (Lov00 0004 03)

A line graph titled 'Acute Major Coronary Events (Primary Endpoint)' showing the proportion of participants without event over 6 years of follow-up. Two lines compare Lovastatin and placebo, indicating a 37% risk reduction for Lovastatin with a p-value less than 0.001.*

FDA Label Image

Table Vii (Lov00 0005 04)

Table listing drug interactions associated with increased risk of myopathy or rhabdomyolysis with Lovastatin. It includes interacting agents such as strong CYP3A4 inhibitors, HIV protease inhibitors, gemfibrozil, cyclosporine, and others, along with prescribing recommendations like contraindications, dosage limits, and to avoid grapefruit juice.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.